Next Article in Journal
Magnetoferritin: Process, Prospects, and Their Biomedical Applications
Previous Article in Journal
The Adaptive Mechanism of Plants to Iron Deficiency via Iron Uptake, Transport, and Homeostasis
Previous Article in Special Issue
Structural Identification of Antibacterial Lipids from Amazonian Palm Tree Endophytes through the Molecular Network Approach
Article Menu
Issue 10 (May-2) cover image

Export Article

Open AccessReview

A Role for Lipid Mediators in Acute Myeloid Leukemia

Department of Medicine B, Ruppin General Hospital, Brandenburg Medical School, 16816 Neuruppin, Germany
Department of Internal Medicine III, University of Munich, 81377 Munich, Germany
Medical Department, Campus Virchow Klinikum, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Int. J. Mol. Sci. 2019, 20(10), 2425;
Received: 12 March 2019 / Revised: 5 May 2019 / Accepted: 6 May 2019 / Published: 16 May 2019
(This article belongs to the Special Issue Bioactive Lipids and Lipidomics 2018)
PDF [946 KB, uploaded 16 May 2019]


In spite of therapeutic improvements in the treatment of different hematologic malignancies, the prognosis of acute myeloid leukemia (AML) treated solely with conventional induction and consolidation chemotherapy remains poor, especially in association with high risk chromosomal or molecular aberrations. Recent discoveries describe the complex interaction of immune effector cells, as well as the role of the bone marrow microenvironment in the development, maintenance and progression of AML. Lipids, and in particular omega-3 as well as omega-6 polyunsaturated fatty acids (PUFAs) have been shown to play a vital role as signaling molecules of immune processes in numerous benign and malignant conditions. While the majority of research in cancer has been focused on the role of lipid mediators in solid tumors, some data are showing their involvement also in hematologic malignancies. There is a considerable amount of evidence that AML cells are targetable by innate and adaptive immune mechanisms, paving the way for immune therapy approaches in AML. In this article we review the current data showing the lipid mediator and lipidome patterns in AML and their potential links to immune mechanisms. View Full-Text
Keywords: AML; immune therapy; PGE2; omega-3; omega-6; lipidomics AML; immune therapy; PGE2; omega-3; omega-6; lipidomics

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Loew, A.; Köhnke, T.; Rehbeil, E.; Pietzner, A.; Weylandt, K.-H. A Role for Lipid Mediators in Acute Myeloid Leukemia. Int. J. Mol. Sci. 2019, 20, 2425.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top